<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343248">
  <stage>Registered</stage>
  <submitdate>26/07/2011</submitdate>
  <approvaldate>27/07/2011</approvaldate>
  <actrnumber>ACTRN12611000784910</actrnumber>
  <trial_identification>
    <studytitle>CUV038: Measurement of drug blood levels over time in healthy male volunteers</studytitle>
    <scientifictitle>A Study to Determine the Pharmacokinetics and Melanogenic Potential of a Controlled-Release Formulation of Afamelanotide in Healthy Male Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CUV038</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The drug is intended to treat patients with light exposure disorders (for example UV light).</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Afamelanotide is a peptide molecule. The drug is a 16mg controlled-release, bioresorbable subcutaneous implant. This study seeks to determine the drug release profile over a 14 day period.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Afamelanotide plasma concentration-time profile.</outcome>
      <timepoint>Collection of blood samples for analysis of afamelanotide concentrations, at the
following time points; Day 0 (prior to implant administration; T=0 hours), Day 1 (2
hours, 4 hours, 8 hours, 12 hours, 24 hours and 36 hours after implant administration),
Day 2 (48 hours), Day 3 (72 hours), Day 4 (96 hours), Day 7 (168 hours), Day 10 (240
hours) and Day 14 (336 hours).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To confirm the safety and tolerability of afamelanotide in healthy male volunteers.</outcome>
      <timepoint>Measurement of melanin density on Day 0, 7, 10, 14, 21, 28, 60 and 90 days and safety monitoring up to 90 days inclusive.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adult males with Fitzpatrick skin types I, II or III aged between 18 and 45 years
(inclusive).
* Free of significant abnormal findings as determined during the screening procedure by surgical and medical history, physical examination, ECG, clinical laboratory testing and vital signs.
* BMI between 18 and 30 kg/m2.
* No history of drug abuse, licit or illicit (including alcohol).
* Agree not to use any medications (prescribed, over-the-counter or complementary medications) without pre-approval by the Principal Investigator during the 7 days preceding the study, and during the course of the study (until Day 90).
* Willing to take precautions to prevent pregnancy with their partner until completion of the study (Day 90) and 30 days thereafter.
* Able to understand and sign the written Informed Consent Form.
* Able and willing to follow the Protocol requirements, including refraining from the use of tanning products and excessive UV light exposure from the start of the study until Day 90</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>* Any personal history of melanoma or dysplastic nevus syndrome.
* Any significant history of allergy and/or sensitivity to any of the contents of study drug
product.
* Any significant history of allergy and/or sensitivity to lignocaine.
* Any significant illness during the 4 weeks before the study screening period.
* Any contraindication to blood sampling.
* Any factor that may interfere with the skin reflectance measurements (e.g. excessive moles, freckles or excessively hairy skin).
* Regularly drinks more than 4 standard drinks of alcohol per day (1 standard drink = 300 mL
beer, 1 glass wine, 1 measure spirit).
* Participation in any clinical study during the 6 weeks before the study screening period.
* Has donated 400 mL or more of blood or had significant blood loss during the 8 weeks
preceding screening.
* Has donated plasma within the 7 days preceding screening.
* Solarium use in the three months prior to study involvement and throughout the duration of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Consenting and eligible subjects are implanted with active investigational medicinal product and all other study procedures are then conducted.</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Clinuvel Pharmaceuticals Limited</primarysponsorname>
    <primarysponsoraddress>Level 14, 190 Queen St, 
Melbourne, Victoria 3000
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Clinuvel Pharmaceuticals Limited</fundingname>
      <fundingaddress>Level 14, 190 Queen St, 
Melbourne. Victoria 3000 
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>CPR Pharma Services Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress>Suite C
32 West Thebarton Rd
THEBARTON SA 5031</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to measure drug blood levels in health male volunteers over a 14 day period. in addition, it is intended to assess the safety and effect of the drug in study subjects over a 90 day period.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University SA Human Research Ethics Committee</ethicname>
      <ethicaddress>Research and Innovation Services
 Mawson Lakes Campus 
University of South Australia 
GPO Box 2471 
Adelaide
 South Australia 5001 
http://www.unisa.edu.au/res/ethics/default.asp</ethicaddress>
      <ethicapprovaldate>4/07/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>15/06/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sumith Nawaratne</name>
      <address>Director, Clinical Research
Clinuvel Pharmaceuticals Ltd 
Level 14, 190 Queen St, 
Melbourne Victoria 3000 Australia</address>
      <phone>+61 3 9660 4900</phone>
      <fax />
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lee Thomas</name>
      <address>Office Manager 
Clinuvel Pharmaceuticals Ltd 
Level 14 / 190 Queen Street
Melbourne Victoria 3000 Australia</address>
      <phone>+61 3 9660 4900</phone>
      <fax>+61 3 9660 4999</fax>
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sumith Nawaratne</name>
      <address>Director, Clinical Research
Clinuvel Pharmaceuticals Ltd 
Level 14, 190 Queen St, 
Melbourne Victoria 3000 Australia</address>
      <phone>+61 3 9660 4900</phone>
      <fax />
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>